MaxCyte

Youtube Subscribe

Open: 5.14 Close: 5.03 Change: -0.11

You're running out of time to find out about MaxCyte Company Inc Stock using an AI.

How much time have you spent trying to decide whether investing in MaxCyte? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about MaxCyte are: platform, cell, …

Concept Map

Semantic Network

Stock Summary

MaxCyte shares fall as revenue plummets in first half, loss widens. CEO Douglas Doerfler sold 14,968 shares of Maxcyte stock in a transaction dated Tuesday, June 27th. MaxCyTe.

Today's Summary

MaxCyte has signed a new strategic platform license with Imugene Limited. MaxCytes cell engineering seminar is just a day away! Join us in Chicagos Fulton Market District to hear how Vimal Keerthi uses our scalable transfection platforms to engineer primary cells, stem cells, and other hard-to-transfection cell lines.

Today's News

MaxCyte has signed a new strategic platform license with Imugene Limited. MaxCytes cell engineering seminar is just a day away! Join us in Chicagos Fulton Market District to hear how Vimal Keerthi uses our scalable transfection platforms to engineer primary cells, stem cells, and other hard-to-transfection cell lines. MaxCyte has signed a new strategic platform license with Imugene Limited, a clinical-stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. MaxCyte, Inc. obtains non-exclusive clinical and commercial rights to use MaxCytes Flow Electroporation® technology and ExPERT™ platform. In return, Maxcyte is entitled to receive platform licensing fees and program-related revenue.

Stock Profile

" MaxCyte shares fall as revenue plummets in first half, loss widens. CEO Douglas Doerfler said: We will continue to make the necessary investments into key aspects of our technology and support offering, including our applications lab, and process development capabilities, which we believe enable us to provide invaluable support to our partners. MaxCyte is a cellular engineering firm whose proprietary platform allows clients to modify cells. Gilead expands CAR-T deal with Maxcyte, Precision files for $100m IPO. Lyell expands our exposure to solid tumor indications which opens up a significant commercial revenue opportunity for MaxCyte. CEO Douglas Doerfler sold 14,968 shares of Maxcyte stock in a transaction dated Tuesday, June 27th."

Keywords

This document will help you to evaluate MaxCyte without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about MaxCyte are: platform, cell, MaxCyte, new, sign, strategic, license, and the most common words in the summary are: maxcyte, inc, cell, science, sign, technology, new, . One of the sentences in the summary was: MaxCyte has signed a new strategic platform license with Imugene Limited. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #maxcyte #inc #cell #science #sign #technology #new.

Read more →

Youtube Subscribe

---